Ethynylated Heterodinucleotide Cytostatic Drugs for a better Cancer Therapy
Our invention describes so called duplex drugs by using phosphodiester bounding as a linker between two nucleoside analogues. Their in vivo metabolism delivers a mixture of highly active antimetabolites. First experimental data demonstrate advantages of our duplex drugs compared to classical nucleoside analogues against some types of cancer cells.
Further Information: PDF
Eberhard Karls Universität Tübingen
Phone: +49 (7071) 29-72639
Contact
Dr. Rolf Hecker
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Groundbreaking images of root chemicals
… offer new insights on plant growth. Technology used in cancer research leads to roadmap of chemicals important for agriculture, food production and climate resilience. On a sunny springtime stroll…
Induction of a torpor-like state with ultrasound
Chen’s team used ultrasound to safely, noninvasively induce a torpor-like state in mice, rats. Some mammals and birds have a clever way to preserve energy and heat by going into…
Chip-based QKD achieves higher transmission speeds
Quantum key distribution system based on integrated photonics lays groundwork for network implementation. Researchers have developed a quantum key distribution (QKD) system based on integrated photonics that can transmit secure…
